Nivea Maker Beiersdorf Cuts Guidance for 2026, Citing Market Conditions
Beiersdorf trimmed its full-year guidance on Monday on slower-than-expected recovery at its core brand Nivea and other economic headwinds.

The Santa Barbara, California-based beauty brand plans to list its shares on Nasdaq under the symbol OLPX.

The Santa Barbara, California-based beauty brand plans to list its shares on Nasdaq under the symbol OLPX.

The world’s biggest maker of beauty products is hoping to capture a market that it estimates at 100 million middle-class consumers.

The world’s biggest maker of beauty products is hoping to capture a market that it estimates at 100 million middle-class consumers.

Behind Balmain’s Kendall-Gigi ‘hair swap’ is the largely unknown Balmain Hair Couture line, once a licensing business, which its owners say now operates ‘like a division of Balmain’ and has plans to expand.

Behind Balmain’s Kendall-Gigi ‘hair swap’ is the largely unknown Balmain Hair Couture line, once a licensing business, which its owners say now operates ‘like a division of Balmain’ and has plans to expand.
ADVERTISEMENT
ADVERTISEMENT
Beiersdorf trimmed its full-year guidance on Monday on slower-than-expected recovery at its core brand Nivea and other economic headwinds.
The refillable clean makeup brand will enter the complexion category as it makes its debut across over 700 Ulta Beauty doors.
The retailer is considering lowering the investment cost for late backers who came in at a valuation of up to $64 billion as it prepares to list at a much lower value, people familiar with the matter said.
As shoppers incorporate weight-loss drugs and more sophisticated skincare into their daily routines, a cottage industry is growing.
The fashion icon, as famous for his singular talent as a scandal that cost him one of the industry’s top jobs, will become one of only three living designers to get a major solo exhibition at the museum.
Abbvie reported second quarter profit and sales that topped expectations, driven by strong demand across its immunology and neuroscience franchises and further signs of a recovery in Botox.
The German sports brand posted a narrower loss in the second quarter as it pushed ahead with an effort to restore growth next year.
DSM-Firmenich beat market expectations for second-quarter core earnings, said full-year sales growth should reach the upper end of its target range on the back of broad-based volume growth.